Spanish biopharmaceutical group expands in Australia 20 October 2010 The Spanish biopharmaceutical group of companies, Grifols SA, has invested in an expansion of its diagnostic plant in Melbourne, Australia. The Barcelona-based Grifols group researches, develops, manufactures and markets plasma derivatives, IV therapy, enteral nutrition, diagnostic systems and medical materials. In 2009, Grifols acquired the Australian-Swiss diagnostics business whose Swiss subsidiary had developed MDmulticard®, a new card technology for blood group typing that is complementary to its DG Gel® card range, used for the fast determination of blood groups. Grifols’ 9 million Euros investment package is being used to increase production of blood group identification cards at both its Swiss and Australian subsidiaries. In Melbourne, the company has installed two new production lines for DG Gel® cards. The Grifols group includes 26 health sector companies from around the world. More information |